Physician profile
Robert M Cleary
NPI 1801865019
$2,925.00
in general payments reported to CMS, 2019-2025
24 companies · $675 in 2025
The $675 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,004 · 2020: $211 · 2022: $297 · 2023: $537 · 2024: $201 · 2025: $675.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,413.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,412.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $403.71 | 2019-2025 | Diamondback Coronary, Jot Dx, Aveir |
| Abiomed | $346.03 | 2023-2024 | Impella |
| Medtronic, INC. | $321.32 | 2022-2025 | Corevalve Evolut R, Venaseal |
| Janssen Pharmaceuticals, INC | $227.18 | 2019-2020 | |
| Amgen INC. | $200.11 | 2019-2020 | |
| Inari Medical, INC. | $190.75 | 2022-2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $180.12 | 2023-2025 | Lifevest |
| Sanofi-Aventis U.S. LLC | $179.72 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $167.19 | 2019-2020 | |
| Baxter Healthcare | $118.44 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
| Novartis Pharmaceuticals Corporation | $89.34 | 2019-2020 | |
| Amarin Pharma, INC. | $68.54 | 2019-2020 | |
| Pfizer INC. | $67.78 | 2019-2025 | |
| Kestra Medical Technology Services, INC. | $64.68 | 2025 | Assure Wcd |
| E.R. Squibb & Sons, L.L.C. | $64.28 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.99 | 2019-2020 | |
| Boston Scientific Corporation | $43.35 | 2022-2023 | Watchman Access System |
| Lundbeck LLC | $37.38 | 2019 | |
| Astellas Pharma US INC | $22.80 | 2019 | |
| Merck Sharp & Dohme LLC | $21.70 | 2022 | |
| Cardiva Medical, INC. | $15.90 | 2023 | Cardiva Vascade Mvp Vvcs 6-12f |
| Actelion Pharmaceuticals US, INC. | $15.90 | 2019 | |
| Edwards Lifesciences Corporation | $12.68 | 2019 | |
| Cardiovascular Systems INC. | $10.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Cleary listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.